This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook GSK’s vaccine leverages GMMA technology. GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. Credit: viewimage/Shutterstock.
The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine development by leveraging local health-tech ecosystems and research infrastructure. Credit: Department of Health Abu Dhabi.
In a vote of 5 to 1 on Thursday, members of the Advisory Committee on Immunization Practices (ACIP) voted to recommend against influenza vaccine containing the preservative thimerosal. The recommendations include all US adults as well as recommending pregnant women also receive a thimerosal-free vaccine for influenza.
A magnifying glass examining a vintage vaccine vial surrounded by four minimalistic chart icons, symbolizing healthcare, medicine, and analytics in the context of global health monitoring. With their technical and methodological improvements, advanced techniques provide valuable information on overall product mass profiles.
FDA approvals dropped in May to 14 drugs after hitting 20 and above in the two months prior, but the total of 84 OKs so far in 2025 is the second only to 2024’s record high for the first part of the year, according to Clarivate. A long-time leader in vaccines, the U.K.
How will RFK Jr’s American dream for vaccines play out? Experts praise the reforms to rare disease and antimicrobial research, but they worry that some provisions in the EU Pharma Package may harm innovation on the continent, contrary to its stated objectives.
From the Dilantin package insert: “The free acid form of phenytoin is used in DILANTIN-125 Suspension and DILANTIN Infatabs. Pharmaceutical Technology Trends in Manufacturing eBook May 2024. Selecting of the appropriate pharmaceutical alternative requires technical judgment. Mancini, A. Thakar, N. and Chaiyaperm, V.
Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. 2 A prominent aspect of this issue that manufacturers have tried to tackle is medication recognition when transferring pills to containers and packaging. 1-3 Detect-A-Dose Lid Label Covers.
How will RFK Jr’s American dream for vaccines play out? Only 4% of global drugs sales will have patent protection, compared to 12% and 6% in 2022 and 2024. Keytruda, approved to treat a range of solid tumours, was the top selling drug in the world in 2024, netting over $29bn in annual sales.
And country of origin is a complex concept when you're using raw materials from different locations and manufacturing them in a different place or packaging them in a different place. So we'll be looking for that and companies should be looking at that. Related Content Advertisement July 24th 2025 Opposing Reactions as RFK Jr.
mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink. By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.”
The warnings encompassed various forms of lack of compliance in the agency’s view, including product mislabeling, false or misleading claims on packaging, and shortfalls in current good manufacturing practice (CGMP) standards found during laboratory inspections. Implications of RFK Jr.’s Implications of RFK Jr.’s
In 2024, an estimated 40.8 In June 2025, the White House submitted a formal rescissions package to Congress that proposed eliminating billions in foreign aid funding—including over $8 billion allocated to USAID. Most notably, they threaten research intended to develop the first HIV vaccine. million new infections. July 17, 2025.
How will RFK Jr’s American dream for vaccines play out? Anticipated next steps involve generating preclinical candidate data packages, which will include non-human primate studies expected in early 2026. Following these outcomes, Acumen holds exclusive rights to develop up to two development candidates.
How will RFK Jr’s American dream for vaccines play out? The spray’s UK approval follows its launch in Spain in 2024 and in Germany last month. ALK signed an agreement with ARS for the exclusive licensing and commercialisation rights to EURneffy in the UK and EU last year. Don’t let policy changes catch you off guard.
Madrigal accessed a large US market when it won accelerated US Food and Drug Administration (FDA) approval in March 2024 for the first MASH treatment in the region. in 2024, with $103.3m If approved in Europe, Rezdiffra would have the same indication. Don’t let policy changes catch you off guard. of that coming in Q4 alone.
Shifts in sterile manufacturing include isolator tech adoption and packaging tailored to personalized medicine, at-home use, and chronic disease treatments. Sterile capsules for injection. Bottles on the bottling line of the pharmaceutical plant. Machine after checking sterile liquids. .
How will RFK Jr’s American dream for vaccines play out? Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market.
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. Give your business an edge with our leading industry insights.
While some speculate the move is related to an ongoing patent dispute, the panel suggested the transaction also reflects broader strategic concerns, including a cooling vaccine market and a desire to bolster oncology capabilities and mRNA manufacturing scale.
In a new CDC report, investigators found that there was no connection between thimerosal in vaccines and autism or other neurodevelopmental conditions. The properties of thimerosal were documented to contribute to the safe use of multidose vials and packaging of vaccines, such as seasonal and pandemic influenza vaccines.
How will RFK Jr’s American dream for vaccines play out? Since launching Ohtuvayre in August 2024, we have seen rapid and accelerating uptake in the US. Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. Give your business an edge with our leading industry insights.
How will RFK Jr’s American dream for vaccines play out? of equity shares from JB employees at the same price per share as offered to KKR. of equity shares from JB employees at the same price per share as offered to KKR. of equity shares from JB employees at the same price per share as offered to KKR.
How will RFK Jr’s American dream for vaccines play out? This podcast is the first instalment in a series by Sharp, titled Our experience is your strength. Each episode draws upon key learnings gathered across Sharp’s decades of experience as a CDMO, helping to set listeners up for success with their chosen vendor.
How will RFK Jr’s American dream for vaccines play out? In a move towards transparency, the US Food and Drug Administration (FDA) has published more than 200 archived complete response letters (CRLs), which detail reasons for non-approval of drug applications submitted between 2020 and 2024.
EU’s Pharma Package falls short of Europe’s goal of global competitiveness Why can’t the US figure out weight loss drug prices? July 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The companies aim to gain insights that could contribute information towards designing more vaccines.
By GlobalData Learn more about Strategic Intelligence FDA’s strategy on trial designs, vaccines and manufacturing Earlier this month, when the Department of Health and Human Sciences Secretary Robert Kennedy Jr. Give your business an edge with our leading industry insights.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
How will RFK Jr’s American dream for vaccines play out? Antiviral Biktarvy is the company’s top-selling HIV drug, generating global revenue of $13.4bn in 2024, an increase of 13% compared to 2023. Gilead already has several approved HIV treatments and prevention options in the US.
How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest E. Give your business an edge with our leading industry insights.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content